Tumor Intiltrating Lymphocytes (TIL) – VHIO

DRUG2 trials

Sponsors

Vall D Hebron Institute Of Oncology, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL

Conditions

Advanced selected solid tumors: melanomaGerm Cell Tumors refractory to salvage chemotherapynon-small cell lung cancer (NSCLC) and cervical cancer.

Phase 2

Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

RecruitingCTIS2023-506400-99-00

Vall D Hebron Institute Of OncologyAdvanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

Start: 2025-01-15Target: 24Updated: 2025-12-02

A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study

Not yet recruitingCTIS2025-522427-10-00

Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELLGerm Cell Tumors refractory to salvage chemotherapy

Target: 10Updated: 2025-11-04